MiR-593 mediates curcumin-induced radiosensitization of nasopharyngeal carcinoma cells via MDR1

被引:33
作者
Fan, Haoning [1 ]
Shao, Meng [1 ]
Huang, Shaohui [1 ]
Liu, Ying [2 ]
Liu, Jie [2 ]
Wang, Zhiyuan [2 ]
Diao, Jianxin [1 ]
Liu, Yuanliang [1 ]
Tong, Li [1 ]
Fan, Qin [1 ]
机构
[1] Southern Med Univ, Nanfang Hosp, Sch Tradit Chinese Med, Dept Mol Biol, Guangzhou 510515, Guangdong, Peoples R China
[2] Southern Med Univ, Nanfang Hosp, Dept Radiotherapy, Guangzhou 510515, Guangdong, Peoples R China
基金
中国国家自然科学基金;
关键词
radiosensitization; curcumin; multidrug resistance gene 1; microRNA-593; nasopharyngeal carcinoma; BREAST-CANCER; RADIATION; THERAPY; DETERMINANTS; RESISTANCE; IMPACT; MODEL;
D O I
10.3892/ol.2016.4438
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Curcumin (Cur) exhibits radiosensitization effects to a variety of malignant tumors. The present study investigates the radiosensitizing effect of Cur on nasopharyngeal carcinoma (NPC) cells and whether its mechanism is associated with microRNA-593 (miR-593) and multidrug resistance gene 1 (MDR1). A clonogenic assay was performed to measure the radiosensitizing effect. The expression of miR-593 and MDR1 was analyzed by quantitative polymerase chain reaction (qPCR) or western blot assay. A transplanted tumor model was established to identify the radiosensitizing effect in vivo. A luciferase-based reporter was constructed to evaluate the effect of direct binding of miR-593 to the putative target site on the 3' UTR of MDR1. The clonogenic assay showed that Cur enhanced the radiosensitivity of cells. Cur (100 mg/kg) combined with 4 Gy irradiation inhibited the growth of a transplanted tumor model in vivo, resulting in the higher inhibition ratio compared with the radiotherapy-alone group. These results demonstrated that Cur had a radiosensitizing effect on NPC cells in vivo and in vitro; Cur-mediated upregulation of miR-593 resulted in reduced MDR1 expression, which may promote radiosensitivity of NPC cells.
引用
收藏
页码:3729 / 3734
页数:6
相关论文
共 35 条
[1]   Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB [J].
Baldwin, AS .
JOURNAL OF CLINICAL INVESTIGATION, 2001, 107 (03) :241-246
[2]   Nasopharyngeal carcinoma [J].
Chan, ATC ;
Teo, PML ;
Johnson, PJ .
ANNALS OF ONCOLOGY, 2002, 13 (07) :1007-1015
[3]   GRP78 mediates the therapeutic efficacy of curcumin on colon cancer [J].
Chang, Yu-Jia ;
Huang, Chien-Yu ;
Hung, Chin-Sheng ;
Chen, Wei-Yu ;
Wei, Po-Li .
TUMOR BIOLOGY, 2015, 36 (02) :633-641
[4]   A Parsimonious Model for Gene Regulation by miRNAs [J].
Djuranovic, Sergej ;
Nahvi, Ali ;
Green, Rachel .
SCIENCE, 2011, 331 (6017) :550-553
[5]   Dose gradient impact on equivalent dose at 2 Gy for high dose rate interstitial brachytherapy [J].
Hannoun-Levi, Jean-Michel ;
Chand-Fouche, Marie-Eve ;
Dejean, Catherine ;
Courdi, Adel .
JOURNAL OF CONTEMPORARY BRACHYTHERAPY, 2012, 4 (01) :14-20
[6]   Polo-like kinase 1 regulates cell proliferation and is targeted by miR-593*in esophageal cancer [J].
Ito, Tetsuo ;
Sato, Fumiaki ;
Kan, Takatsugu ;
Cheng, Yulan ;
David, Stefan ;
Agarwal, Rachana ;
Paun, Bogdan C. ;
Jin, Zhe ;
Olaru, Alexandru V. ;
Hamilton, James P. ;
Selaru, Florin M. ;
Yang, Jian ;
Matsumura, Nobutoshi ;
Shimizu, Kazuharu ;
Abraham, John M. ;
Shimada, Yutaka ;
Mori, Yuriko ;
Meltzer, Stephen J. .
INTERNATIONAL JOURNAL OF CANCER, 2011, 129 (09) :2134-2146
[7]   The chemopreventive agent curcumin is a potent radiosensitizer of human cervical tumor cells via increased reactive oxygen species production and overactivation of the mitogen-activated protein kinase pathway [J].
Javvadi, Prashanthi ;
Segan, Andrew T. ;
Tuttle, Stephen W. ;
Koumenis, Constantinos .
MOLECULAR PHARMACOLOGY, 2008, 73 (05) :1491-1501
[8]  
JEMAL A, 2011, CA-CANCER J CLIN, V61, P134, DOI [DOI 10.3322/CAAC.20107, DOI 10.3322/caac.20115]
[9]   Curcumin and its Formulations: Potential Anti-Cancer Agents [J].
Ji, Jun-Ling ;
Huang, Xian-Feng ;
Zhu, Hai-Liang .
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2012, 12 (03) :210-218
[10]   MiR-181a confers resistance of cervical cancer to radiation therapy through targeting the pro-apoptotic PRKCD gene [J].
Ke, G. ;
Liang, L. ;
Yang, J. M. ;
Huang, X. ;
Han, D. ;
Huang, S. ;
Zhao, Y. ;
Zha, R. ;
He, X. ;
Wu, X. .
ONCOGENE, 2013, 32 (25) :3019-3027